Department of Orthopaedic Surgery, University of Rochester, Rochester, New York, United States.
Davidson College, Davidson, North Carolina.
Global Spine J. 2016 Feb;6(1):e41-6. doi: 10.1055/s-0035-1555660. Epub 2015 Jun 16.
Study Design Case report. Objective There is a paucity of literature describing the use of bone graft substitutes to achieve fusion in the pediatric cervical spine. The outcomes and complications involving the off-label use of bone morphogenetic protein (BMP)-2 in the pediatric cervical spine are not clearly defined. The purpose of this article is to report successful fusion without complications in two pediatric patients who had instrumented occipitocervical fusion using low-dose BMP-2. Methods A retrospective review of the medical records was performed, and the patients were followed for 5 years. Two patients under 10 years of age with upper cervical instability were treated with occipitocervical instrumented fusion using rigid occipitocervical fixation techniques along with conventionally available low-dose BMP-2. A Medline and PubMed literature search was conducted using the terms "bone morphogenetic protein," "BMP," "rh-BMP2," "bone graft substitutes," and "pediatric cervical spine." Results Solid occipitocervical fusion was achieved in both pediatric patients. There were no reported perioperative or follow-up complications. At 5-year follow-up, radiographs in both patients showed successful occipital cervical fusion without evidence of instrumentation failure or changes in the occipitocervical alignment. To date, there are few published reports on this topic. Complications and the appropriate dosage application in the pediatric posterior cervical spine remain unknown. Conclusions We describe two pediatric patients with upper cervical instability who achieved successful occipital cervical fusion without complication using off-label BMP-2. This report underscores the potential for BMP-2 to achieve successful arthrodesis of the posterior occipitocervical junction in pediatric patients. Use should be judicious as complications and long-term outcomes of pediatric BMP-2 use remain undefined in the existing literature.
病例报告。目的:描述使用骨移植替代物在儿科颈椎中实现融合的文献很少。骨形成蛋白(BMP)-2 在儿科颈椎中的非适应证使用的结果和并发症尚不清楚。本文的目的是报告两例使用低剂量 BMP-2 进行仪器化枕颈融合术的儿科患者成功融合且无并发症。方法:对病历进行回顾性分析,对患者进行了 5 年随访。两名年龄在 10 岁以下的上颈椎不稳定患者采用刚性枕颈固定技术进行枕颈器械融合,并结合常规低剂量 BMP-2。使用术语“骨形成蛋白”、“BMP”、“rh-BMP2”、“骨移植替代物”和“儿科颈椎”进行 Medline 和 PubMed 文献检索。结果:两名儿科患者均实现了牢固的枕颈融合。无报告围手术期或随访并发症。5 年随访时,两名患者的 X 线片均显示枕颈融合成功,无器械失败或枕颈排列改变的证据。迄今为止,关于这个主题的报道很少。在儿科后颈椎中,并发症和适当的剂量应用仍不清楚。结论:我们描述了两名上颈椎不稳定的儿科患者,他们使用非适应证 BMP-2 成功地实现了枕颈融合,且无并发症。该报告强调了 BMP-2 在后枕颈交界处实现成功关节融合的潜力。在现有文献中,儿童 BMP-2 使用的并发症和长期结果仍不明确,因此应谨慎使用。